You reviewed .... for this content
out of 5
5...
4...
3...
2...
1...
Event : ESC Congress 2013
Topic : Other
Discussant: thrombosis and antithrombotic therapy.
Reduction in recurrent ischemic events with vorapaxar: results from TRACER
Perioperative management of oral antiplatelet therapy in patients with coronary stents undergoing surgery
High on-treatment platelet reactivity, a marker of bleeding risk? an analysis of the ARCTIC study
Rapid onset and offset of action of otamixaban, a potent direct intravenous factor Xa inhibitor.
Clopidogrel pretreatment effect according to the clinical presentation in patients undergoing percutaneous coronary intervention: a meta-analysis
Clinical outcomes for prasugrel versus clopidogrel are consistent among patients from TRITON-TIMI 38 with unstable angina or non-ST-elevation myocardial infarction.
Reversal of dabigatran clotting activity in the rat ex vivo by a specific and selective antibody fragment antidote: are there non-specific effects on warfarin, rivaroxaban and apixaban?
Pharmacodynamic effects of atorvastatin vs. rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy
Clopidogrel resistance in patients with ST-elevation myocardial infarction is associated with high body mass index
Otamixaban versus UFH, enoxaparin and fondaparinux in the prevention of cardiac catheter thrombosis in vitro (electron microscopic results from the OPEN-CATH study).
Comparison of the antiplatelet effect of clopidogrel hydrogeno sulfate and clopidogrel besylate in patients with stable coronary artery disease
Impact of dual non-responsiveness to aspirin and clopidogrel on clinical outcomes in patients treated with drug-eluting stents in the ARCTIC study.
Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study
Dose of aspirin does not inluence laboratory antiplatelet efficacy of P2Y12 inhibitors
Prasugrel reduces agonists inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel
Switching of P2Y12 inhibitor in patients with acute coronary syndrome: Insights from the GReek AntiPlatElet Registry (GRAPE)
International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial
Patterns of antiplatelet therapy in patients who have experienced an acute coronary event: a descriptive study in primary care.
Do changes in high on-treatment platelet reactivity predict cardiovascular events in patients undergoing percutaneous coronary intervention? A meta-regression analysis of 30 randomized clinical trials
Association of 2B3A inhibition with new antiplatelet regimens in the setting of acute coronary syndromes: a meta-analysis of randomized controlled trials
The characteristics of patients with a recent history of acute myocardial infarction and their antiplatelet therapy utilization pattern in the UK general practice
Maximal antiplatelet therapy with prasugrel and GP IIb/IIIa-receptor antagonists in ST-elevation myocardial infarctions is not associated with high acute bleeding rates in clinical practice
Combined therapy with new P2Y12 receptor antagonists (prasugrel and ticagrelor) and bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Long-term outcomes of various antithrombotic strategies in patients with acute coronary syndrome and coexisting indications for anticoagulation
Pretreatment with prasugrel is safe and associated with an improvement outcome in patients with NSTE-ACS
Ticagrelor is frequently discontinued in a real world setting
Dabigatran and rivaroxaban do not influence TRAP, ADP and AA induced platelet aggregation in cardiac patients
Pleiotropic effect of factor Xa inhibitor: fondaparinux inhibites ROS-induced cell proliferation and augments cardioprotective cytokine production in mouse cardiac-derived fibroblast
Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119)
Real life efficacy and safety of dabigatran for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119)
The impact of personalized antiplatelet treatment on early adverse events in PCI-treated patients with high on-clopidogrel platelet reactivity: results of the ISAR-HPR registry
Restoration of platelet function with platelet transfusion in cardiac surgery patients on dual antiplatelet therapy.
Predictors of stent thrombosis from 30 days to 3 years after zotarolimus- vs sirolimus-eluting coronary stent implantation: an analysis from PROTECT
Contemporary use of platelet function and pharmacogenomic testing among acute myocardial infarction patients treated with PCI in the United States: insights from the TRANSLATE-ACS study
Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial
Rapamycin modulates anti- and pro-thrombotic gene expressions via Kruppel-like factor 2: in vitro studies
Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel
Mean platelet volume and platelet count in acute coronary syndrome patients: role of a genetic variants on chr7q22.3 and chr3p13-p21
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation
Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose.
Correlation of clinical findings and clot ultrastructure in coronary and peripheral arterial thrombi
Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study
Differences in platelet microRNA profiles after aspirin use are associated with differences in whole blood aggregation and might identify aspirin resistance.
Prasugrel, but not clopidogrel, is effective in platelet inhibition in patients treated by therapeutic hypothermia after cardiac arrest for acute myocardial infarction.
High rate of ticagrelor and prasugrel- non-responder in patients in therapeutic hypothermia after cardiac arrest
Randomized comparison of the platelet inhibitory efficacy between low dose prasugrel and standard dose clopidogrel in patients receiving dual antiplatelet therapy after coronary stent implantation
Management of cardiac surgery patients with Heparin-Induced Thrombocytopenia (HIT-II): experience with preoperative plasmaphereses plus intraoperative heparin.
Stent thrombosis after primary angioplasty - incidence, timing and long term prognostic: 5 year follow-up registry
Mean platelet volume is associated with infarct size and microvascular obstruction estimated by cardiac magnetic resonance in ST segment elevation myocardial infarction
High neutrophils and low CD34+ cell count are associated with increased risk of venous thromboembolism
TAILOR- Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention
Ticagrelor or prasugrel in STEMI patients: a pharmacodynamic evaluation
Identification of a new biomarker for in vivo evaluation of blood coagulation and platelet activation
Acute effects of clopidogrel are predicted by integrity of prostacyclin signalling.
Enhanced platelet reactivity in pediatric depression: an observational study.
Long-term outcomes in patients with early, late and very late stent thrombosis after bare metal stenting
Onset of antiplatelet effect of prasugrel and ticagrelor is delayed in patients with acute coronary syndromes
Preliminary experience of a national outpatient stent thrombosis clinic to achieve tailor-made antiplatelet therapy in stent thrombosis patients
Abnormal platelet aggregability in response to treadmill exercise in diabetic patients without documented coronary artery disease.
Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial
An unexpected risk predictor in acute coronary syndromes.
Mean platelet volume during the course of STEMI and primary PCI
Platelet aggregation and fibrin clot structure in patients with coronary artery disease and previous myocardial infarction
Impact of ranitidine on platelet aggregation in patients taking clopidogrel
A new prognostic risk score including platelet reactivity for bleeding after percutaneous coronary intervention via the femoral approach
Measurement of the effect of platelet activators and heparin on adhesion and spreading of human platelets using impedimetry
Influence of CYP2C19 *2 and *3 loss-of-function alleles on phenotyping and clopidogrel pharmacodynamics
Obesity and a history of low response to clopidogrel treatment are predictors for a reduced antiplatelet action of prasugrel treatment
Effect of rabeprazole versus famotidine on platelet inhibition in patients with normal clopidogrel responsiveness: result of the ACCEL-PROTECT randomized study
Safety and efficacy of policosanol to improve high on clopidogrel platelet reactivity after percutaneous coronary stent implantation
Pharmacodynamic effect of cilostazol versus clopidogrel in stented patients during proton pump inhibitor co-administration: the result of the ACCEL-PARAZOL study
In-hospital bleeding in the era of newer P2Y12 inhibitors in real-life patients with acute coronary syndrome: results from the GReek AntiPlatElet (GRAPE) registry
Pharmacodynamic effect of adjunctive cilostazol vs. high-dos clopidogrel in acute coronary syndrome patients according to the CYP2C19 genotype (ACCEL-GENOTYPE) study
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy
Get your access to resources
Our mission: To reduce the burden of cardiovascular disease
